Last updated: September 7, 2026
Acalabrutinib, marketed by AstraZeneca as Calquence, has become a major targeted-therapy asset in B-cell malignancies. Its commercial growth is driven by first-line chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), broader use of tablet formulations, and competitive share gains against ibrutinib. AstraZeneca reported approximately $3.1 billion in Calquence product sales for 2024, up from roughly $2.5 billion in 2023 and about $2.0 billion in 2022.[1]
The principal market risk is not biosimilar erosion. Acalabrutinib is a small molecule, so future competition will come from ANDA-based generic applicants, other covalent BTK inhibitors, noncovalent BTK inhibitors, fixed-duration combination regimens, and next-generation therapies.
What is acalabrutinib and how is Calquence used?
Acalabrutinib is an orally administered, covalent Bruton’s tyrosine kinase (BTK) inhibitor. It irreversibly binds BTK and suppresses B-cell receptor signaling, which is central to the growth and survival of several B-cell cancers.
Calquence is approved in the United States for:
- Adults with CLL or SLL.
- Adults with MCL who have received at least one prior therapy, subject to the regulatory history of the indication.
- Certain adult patients with previously untreated MCL under an accelerated-approval framework tied to confirmatory evidence.
The product is available in 100 mg capsules and 100 mg tablets. The tablet formulation has commercial significance because it can be administered without regard to food and reduces some administration constraints associated with the capsule presentation.[2]
What is the FDA regulatory status of acalabrutinib?
The FDA granted the first Calquence approval in October 2017 for adults with MCL who had received at least one prior therapy. The FDA later approved Calquence for CLL and SLL in November 2019. The agency approved a tablet formulation and expanded labeling in subsequent actions, supporting use across the principal CLL/SLL treatment population.[2]
Acalabrutinib’s strongest commercial indication is CLL/SLL. The CLL market is larger than the relapsed MCL market and has supported migration of Calquence from later-line use into first-line treatment.
How has acalabrutinib revenue developed?
AstraZeneca’s reported Calquence sales have grown rapidly since launch.
| Fiscal year |
Approximate Calquence sales |
Commercial position |
| 2021 |
About $1.2 billion |
Expansion in CLL/SLL |
| 2022 |
About $2.0 billion |
Increasing first-line adoption |
| 2023 |
About $2.5 billion |
Continued share gains in CLL |
| 2024 |
About $3.1 billion |
Larger global contribution and broader use |
Source: AstraZeneca annual reports and financial results.[1]
The trajectory reflects several factors:
- CLL/SLL is a larger addressable market than relapsed MCL.
- Physicians have increasingly favored second-generation BTK inhibitors over ibrutinib because of differentiated tolerability and reduced cardiovascular concern.
- AstraZeneca has used clinical data to position Calquence in both treatment-naive and previously treated CLL.
- The tablet formulation supports prescribing convenience.
- Calquence has gained from continued penetration outside the United States, particularly in Europe and other developed markets.
The product is now one of AstraZeneca’s key oncology growth assets. Its sales base is large enough that future growth will depend more on market share, treatment duration, geographic penetration and label expansion than on initial market creation.
What is driving the acalabrutinib market?
First-line CLL is the central growth engine
The commercial center of gravity has shifted toward untreated CLL. Calquence competes with ibrutinib, zanubrutinib, venetoclax-based regimens and combination approaches.
AstraZeneca’s ELEVATE-TN study supported Calquence in previously untreated CLL. The company has also used data from the ASCEND and ELEVATE-RR programs to support positioning in relapsed or refractory disease.[3,4]
The CLL treatment market is moving toward risk-adapted and potentially fixed-duration therapy. Continuous BTK inhibitor treatment remains commercially attractive because patients can remain on therapy for extended periods. Fixed-duration venetoclax combinations can limit treatment duration but may offer a different value proposition for payers and patients.
Tolerability supports displacement of ibrutinib
Acalabrutinib was designed as a more selective BTK inhibitor than ibrutinib. The main commercial argument is a lower rate of certain cardiovascular adverse events, particularly atrial fibrillation, while maintaining BTK pathway suppression.
In the head-to-head ELEVATE-RR trial, Calquence demonstrated noninferior progression-free survival against ibrutinib in previously treated high-risk CLL and showed lower rates of atrial fibrillation and several other cardiovascular events.[4]
The tolerability advantage is commercially important because ibrutinib established the BTK inhibitor class but has faced scrutiny over cardiovascular toxicity, bleeding risk and treatment discontinuation.
MCL is valuable but smaller
The MCL opportunity is smaller than CLL/SLL and has greater treatment-line limitations. Calquence competes with ibrutinib, zanubrutinib, brexucabtagene autoleucel, pirtobrutinib and other therapies.
MCL also has greater exposure to treatment sequencing. Patients may receive a BTK inhibitor before cellular therapy or a noncovalent BTK inhibitor, which can shorten duration of use for individual products.
How does acalabrutinib compare with competing BTK inhibitors?
| Drug |
Company |
BTK class |
Principal commercial position |
| Calquence, acalabrutinib |
AstraZeneca |
Covalent, second generation |
CLL/SLL and MCL |
| Imbruvica, ibrutinib |
AbbVie and Janssen |
Covalent, first generation |
Large installed base in B-cell malignancies |
| Brukinsa, zanubrutinib |
BeiGene |
Covalent, second generation |
Strong competitive growth in CLL and MCL |
| Jaypirca, pirtobrutinib |
Eli Lilly |
Noncovalent |
Post-covalent BTK and expanding indications |
| Venclexta, venetoclax |
AbbVie and Roche |
BCL-2 inhibitor |
Fixed-duration and combination competitor |
Brukinsa is the most direct commercial threat. It competes on selectivity, clinical efficacy and global market expansion. Jaypirca is less directly substitutive in the initial treatment setting but may become more important after covalent BTK inhibitor failure.
Calquence’s competitive defense is strongest where clinical data, physician familiarity and tolerability differentiate it from ibrutinib. Its exposure is higher where physicians prioritize fixed-duration treatment or where zanubrutinib achieves superior local access and reimbursement.
What patents protect acalabrutinib?
Acalabrutinib is protected by compound, formulation, pharmaceutical composition and method-of-use patents. The principal U.S. patent estate was developed by Acerta Pharma and is now controlled commercially by AstraZeneca.
| Protection category |
Commercial purpose |
Expected effect |
| Acalabrutinib compound patents |
Protect the active pharmaceutical ingredient |
Core barrier to generic entry |
| Salt and solid-form patents |
Protect specific chemical forms |
May complicate alternative development |
| Tablet and capsule formulation patents |
Protect dosage-form design and excipient combinations |
Can delay or narrow formulation-based challenges |
| Treatment-method patents |
Cover use in CLL, SLL, MCL and related B-cell malignancies |
Support litigation and labeling protection |
| Manufacturing and process patents |
Protect routes, intermediates and specifications |
Increase development complexity |
The primary composition-of-matter protection extends into the mid-2030s, before any patent-term adjustment or pediatric extension. Later-expiring formulation and method patents may extend selected protection beyond the core compound term.
The Orange Book remains the controlling public source for listed Calquence patents and regulatory exclusivity information. FDA patent listings can change through listing updates, corrections, delistings and litigation outcomes.[5]
What formulations are protected by Calquence patents?
Calquence has both capsule and tablet presentations. Formulation protection may cover:
- Tablet compositions.
- Specific crystalline or amorphous forms.
- Stability characteristics.
- Dissolution profiles.
- Excipient combinations.
- Dosage regimens and administration conditions.
A generic applicant can seek approval for a formulation that avoids a listed formulation patent, but it must still address the active-ingredient patents and any method-of-use patents relevant to the proposed label.
When does acalabrutinib lose exclusivity?
The practical U.S. loss-of-exclusivity window is expected to occur in the mid-2030s for the core compound, subject to patent-term adjustment, pediatric exclusivity and the outcome of Paragraph IV litigation.
The earliest generic entry date will not necessarily equal the expiration date of the last Orange Book-listed patent. Entry could occur earlier through:
- A successful Paragraph IV challenge.
- A settlement granting a licensed launch date.
- A non-infringing formulation.
- A carve-out of protected indications.
- A court finding that a patent is invalid, unenforceable or not infringed.
Regulatory exclusivity is separate from patent protection. The original MCL approval carried orphan-drug exclusivity, but that period does not replace the longer-running patent estate. CLL/SLL approval provided the commercial expansion that now drives sales, while patent protection determines the timing of generic competition.
Are companies challenging acalabrutinib patents through Paragraph IV filings?
Publicly disclosed Paragraph IV activity has not produced a material U.S. generic launch against Calquence through the latest reported commercial period. The main reason is the distance between current sales growth and the expected core patent expiry.
A Paragraph IV filing could still arise before the mid-2030s. A generic applicant would likely evaluate:
- The validity of the core compound patent.
- Whether the active ingredient is claimed broadly enough to cover the proposed product.
- The scope of tablet and capsule patents.
- Method-of-use claims covering CLL, SLL or MCL.
- Whether a label carve-out can avoid patented indications.
- Whether patent-term adjustment changes the effective expiry date.
The commercial incentive to challenge will increase as annual Calquence sales approach or exceed $3 billion and as generic development timelines become more compatible with a launch before or shortly after core patent expiry.
What patent litigation affects acalabrutinib?
The most important future litigation risk is an ANDA patent case under the Hatch-Waxman Act. Such a case would normally follow a Paragraph IV notice and could trigger a 30-month stay of FDA approval for the challenged generic, subject to statutory exceptions and court developments.[6]
Potential litigation issues include:
- Obviousness of the acalabrutinib compound.
- Written description and enablement.
- Infringement by tablet or capsule formulations.
- Patent-term adjustment calculations.
- The scope of method-of-use claims.
- Settlement terms governing the first authorized generic or licensed generic entry.
There is no biosimilar pathway for acalabrutinib. Biosimilars apply to biological products, while Calquence is a chemically synthesized small molecule. The relevant pathway is an ANDA or, in some circumstances, a 505(b)(2) application.
What licensing deals created AstraZeneca’s acalabrutinib position?
AstraZeneca obtained global rights to acalabrutinib through its relationship with Acerta Pharma. In 2015, AstraZeneca agreed to pay approximately $4 billion upfront for a majority interest and up to approximately $2.5 billion in contingent payments. AstraZeneca later acquired the remaining interest in Acerta.[7]
The transaction gave AstraZeneca an internally controlled BTK inhibitor platform without requiring discovery and early clinical development from the beginning. It also placed Calquence within AstraZeneca’s hematology and oncology commercial infrastructure.
What is the geographic coverage of Calquence?
Calquence has been commercialized across major pharmaceutical markets, including the United States, Europe and other international territories. Geographic performance depends on:
- Regulatory approvals for CLL, SLL and MCL.
- National reimbursement decisions.
- Treatment guidelines.
- Competition from ibrutinib and zanubrutinib.
- Local pricing and tender systems.
- Availability of tablet and capsule formulations.
The United States remains the most important profit pool because of higher net pricing and earlier uptake of novel oncology therapies. International growth expands the patient base but generally produces lower net sales per patient.
How strong is the acalabrutinib patent estate?
The estate is commercially strong through the mid-2030s because it combines core compound protection with formulation and use-based protections. Its principal weakness is temporal rather than structural: once core compound protection expires, formulation and method patents may preserve only partial market control.
Patent strength should be assessed against four factors:
- The enforceability and remaining term of the core composition patent.
- Whether formulation patents cover commercially necessary presentations.
- The ability to defend method-of-use claims against label carve-outs.
- The likelihood that a generic applicant can design around secondary patents.
The estate is stronger against an early, fully substitutable generic than against a narrowly labeled product that avoids selected indications.
What generic launch scenarios exist for Calquence?
Three scenarios are commercially plausible:
| Scenario |
Timing |
Market effect |
| Patent-protected launch |
After core and relevant secondary patents expire |
Rapid price erosion after multiple ANDA approvals |
| Settlement-based entry |
Before full patent expiry under an agreed date |
Gradual erosion, potentially with authorized generic control |
| Successful early challenge |
Before core expiry after litigation |
Abrupt revenue decline and material value transfer to generics |
The first generic entrant could capture substantial share if it launches with a full CLL/SLL label and adequate supply. Multiple entrants would accelerate net-price erosion. Oncology oral generics often experience rapid price compression, although payer contracts, specialty-pharmacy distribution and physician familiarity can moderate the transition.
What is the financial outlook for acalabrutinib?
Calquence is likely to remain a growth product in the near term, but its growth rate should moderate from the rapid expansion recorded between 2022 and 2024.
Upside drivers include:
- Continued conversion from ibrutinib.
- First-line CLL penetration.
- International reimbursement expansion.
- Greater use of tablets.
- Longer treatment duration.
- Growth in community oncology prescribing.
Downside drivers include:
- Brukinsa share gains.
- Increased use of fixed-duration venetoclax regimens.
- Jaypirca adoption after BTK resistance.
- Treatment discontinuation caused by adverse events.
- Pricing pressure in Europe.
- Patent litigation and earlier generic entry.
At approximately $3.1 billion in 2024 sales, Calquence is material to AstraZeneca’s oncology portfolio. A continued low- to mid-teens growth rate would create several billion dollars of additional cumulative sales before generic entry. The valuation risk becomes more significant after 2030 because investors will increasingly discount the timing of generic competition and the durability of secondary patent protection.
Key Takeaways
- Calquence is AstraZeneca’s acalabrutinib product for CLL, SLL and MCL.
- Reported sales rose from about $2.0 billion in 2022 to approximately $3.1 billion in 2024.
- First-line CLL is the principal growth market.
- The main branded competitors are ibrutinib, zanubrutinib and pirtobrutinib.
- Calquence’s strongest clinical differentiation is its second-generation BTK selectivity and cardiovascular tolerability profile.
- The core patent estate is expected to protect the product into the mid-2030s, subject to patent-term adjustments and litigation.
- Generic rather than biosimilar competition will determine long-term erosion.
- AstraZeneca’s 2015 Acerta transaction created the commercial and patent platform for Calquence.
- The largest medium-term risks are Brukinsa share gains, fixed-duration treatment, Jaypirca sequencing and earlier-than-expected Paragraph IV litigation.
FAQs
Is acalabrutinib better than ibrutinib?
Acalabrutinib has a more selective BTK profile and showed lower atrial-fibrillation rates than ibrutinib in the ELEVATE-RR trial, while maintaining noninferior progression-free survival in previously treated high-risk CLL.[4]
Is Calquence a chemotherapy drug?
No. Calquence is an oral targeted therapy that inhibits BTK. It is not conventional cytotoxic chemotherapy.
Does Calquence have a biosimilar competitor?
No. Acalabrutinib is a small molecule, so future competition will involve chemical generics rather than biosimilars.
Which company makes Calquence?
AstraZeneca markets Calquence globally. The product originated with Acerta Pharma, which AstraZeneca acquired through a staged transaction.
What is the biggest commercial threat to Calquence?
The most immediate branded threat is zanubrutinib, marketed as Brukinsa by BeiGene. The longer-term threat is generic acalabrutinib entry after the core patent estate expires or is successfully challenged.
References
- AstraZeneca. (2025). Annual report and Form 20-F 2024. AstraZeneca plc.
- U.S. Food and Drug Administration. (2017-2024). Calquence: FDA prescribing information and approval history. FDA.
- Sharman, J. P., Egyed, M., Jurczak, W., et al. (2020). Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia. The Lancet, 395(10232), 1278-1288.
- Byrd, J. C., Hillmen, P., O’Brien, S., et al. (2021). Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 39(31), 3441-3452.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355.
- AstraZeneca. (2015-2017). Acerta Pharma transaction announcements. AstraZeneca plc.
